Veterinary Neurodegenerative Disease Diagnostics Market Size & Growth Forecast 2027–2036, By Segments (Indication, Animal Type, Diagnostic Tests, End Use, Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
Veterinary Neurodegenerative Disease Diagnostics Market size was estimated at USD 421.9 million in 2026 and is projected to grow at a 9.22% CAGR from 2027 to 2036, crossing USD 1.02 billion by 2036. The industry revenue for 2027 is assessed at USD 454.93 million.
Get more details on this report
Request Free Sample ReportVeterinary Neurodegenerative Disease Diagnostics Market Intelligence Snapshot
Regional Market Dynamics
- North America held 41.31% of the market in 2026, supported by advanced veterinary infrastructure, specialized diagnostic services, growing pet ownership, and increased emphasis on neurological assessment and preventive animal healthcare.
- Asia Pacific is projected to grow fastest as pet ownership rises, veterinary infrastructure expands, and specialty animal hospitals and diagnostic capabilities develop, supporting greater demand for early neurological disease detection.
Segment Momentum
- Cognitive dysfunction accounted for 42.77% of the market in 2026 and is also the fastest-growing indication. Greater awareness of age-related behavioral changes and demand for timely veterinary assessment are supporting diagnostic adoption.
- Imaging is the largest and fastest-growing diagnostic test segment, supported by its ability to identify structural abnormalities and inform clinical assessment. Improved imaging capabilities and wider access to specialized veterinary facilities are strengthening adoption.
Market Expansion Drivers
- Adoption of advanced neurodiagnostic tools in veterinary clinics.
- Development of biomarkers for early neurodegenerative detection.
- Expansion of veterinary healthcare infrastructure in emerging regions.
Leading Market Participants
- Prominent players in the veterinary neurodegenerative disease diagnostics market include IDEXX Laboratories (USA), Zoetis (USA), Virbac (France), Life Diagnostics (USA), ACUVET BIOTECH (UK), Merck & Co. (USA), MI:RNA Diagnostics (UK), Mercodia AB (Sweden), Antech Diagnostics (USA), Avacta Animal Health (UK).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 421.9 million
- 2027 Estimated Market Size: USD 454.93 million
- Projected Market Size: USD 1.02 billion by 2036
- Growth Forecast: 9.22% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Indication (Cognitive Dysfunction) | Animal Type (Companion) | Diagnostic Tests (Imaging) | End Use (Veterinary Hospitals and Clinics) | Product (Consumables, Reagents & Kits)
- Emerging Opportunity Segment: Indication (Cognitive Dysfunction) | Animal Type (Companion) | Diagnostic Tests (Imaging) | End Use (Veterinary Hospitals and Clinics) | Product (Consumables, Reagents & Kits)
Market Growth Drivers and Industry Trends
Adoption of Advanced Neurodiagnostic Tools in Veterinary Clinics
The adoption of advanced neurodiagnostic tools in veterinary clinics is driving market growth by improving the ability of veterinarians to identify neurological abnormalities and distinguish between different causes of neurological disorders. Modern imaging, laboratory testing, and neurological assessment technologies enable more comprehensive evaluation of animals presenting with cognitive, motor, or behavioral changes. Growing emphasis on accurate diagnosis and individualized veterinary care is encouraging clinics to strengthen their diagnostic capabilities and incorporate more sophisticated neurodiagnostic solutions.
Development of Biomarkers for Early Neurodegenerative Detection
The development of biomarkers for early neurodegenerative detection is supporting market expansion by enabling veterinarians and researchers to identify disease-related changes before severe neurological deterioration occurs. Biomarker-based approaches can improve diagnostic confidence, support disease monitoring, and facilitate earlier intervention strategies. Continued research into molecular indicators associated with neurological disorders is expanding the range of diagnostic possibilities and encouraging greater adoption of specialized testing methods across veterinary research and clinical settings.
Expansion of Veterinary Healthcare Infrastructure in Emerging Regions
The expansion of veterinary healthcare infrastructure in emerging regions is creating favorable conditions for the growth of neurodegenerative disease diagnostics by improving access to specialized animal healthcare services and diagnostic facilities. Increasing availability of veterinary hospitals, laboratories, imaging centers, and trained professionals is enabling more complex neurological conditions to be evaluated and managed locally. As awareness of companion animal health and advanced veterinary care increases, investment in diagnostic capabilities is expected to strengthen demand for specialized neurological testing.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Adoption of advanced neurodiagnostic tools in veterinary clinics | 3% | Short term (≤ 2 yrs) | North America; Europe; Spillover: Asia Pacific | Medium | Fast |
| Development of biomarkers for early neurodegenerative detection | 2% | Medium term (2–5 yrs) | Europe; North America; Spillover: Asia Pacific | High | Moderate |
| Expansion of veterinary healthcare infrastructure in emerging regions | 1.5% | Long term (5+ yrs) | Asia Pacific; Latin America; Spillover: MEA | Low | Moderate |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America accounted for the largest share of the veterinary neurodegenerative disease diagnostics market, with 41.31% share in 2026. The region's strong position is backed by advanced veterinary healthcare infrastructure, increasing awareness of companion animal neurological disorders, and wider access to specialized diagnostic services. Veterinarians are increasingly relying on sophisticated imaging, laboratory testing, and neurological assessments to identify conditions that affect the brain, spinal cord, and nervous system of animals. Growing pet ownership and stronger emphasis on animal health and preventive care are also encouraging owners to seek veterinary attention when neurological symptoms emerge. Continued improvements in veterinary research, specialist care, and diagnostic capabilities are supporting the adoption of more precise approaches to identifying neurodegenerative conditions and improving clinical management.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is expected to grow at the fastest pace in the veterinary neurodegenerative disease diagnostics market, supported by expanding veterinary infrastructure, rising pet ownership, and growing awareness of advanced animal healthcare. As companion animals increasingly become part of households, owners are showing greater willingness to invest in diagnostic and treatment services that can improve their animals' quality of life. Urbanization and changing lifestyles are also contributing to higher demand for organized veterinary services, particularly in major cities. Improvements in veterinary education and access to specialized diagnostic technologies are helping practitioners identify neurological conditions more effectively. The gradual development of specialty animal hospitals and increasing emphasis on early diagnosis are expected to further support market expansion across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
United States 🇺🇸
Advanced Companion DiagnosticsThe U.S. market is prioritizing earlier and more objective identification of neurodegenerative conditions in companion animals through imaging, biomarker analysis, and specialized neurological assessment. Diagnostic providers can focus on clinically actionable testing, integration with veterinary referral networks, and tools that support longitudinal disease monitoring.
Germany 🇩🇪
Precision Veterinary NeurologyGermany’s veterinary diagnostics priorities emphasize reliable differentiation of neurological disorders and stronger clinical evidence for specialized testing. Opportunities center on advanced imaging, laboratory biomarkers, and standardized diagnostic workflows that help veterinary practices identify disease progression while supporting more informed treatment and monitoring decisions.
Japan 🇯🇵
Aging-Pet Neurology DiagnosticsJapan’s veterinary neurodegenerative diagnostics market is shaped by the clinical needs associated with aging companion animals. Providers can prioritize accessible neurological screening, imaging support, biomarker-based assessment, and monitoring tools that help veterinarians distinguish age-related cognitive changes from other neurological conditions.
South Korea 🇰🇷
Technology-Enabled Neurological TestingSouth Korea’s market priorities favor technology-supported veterinary diagnostics, with opportunities for advanced imaging, laboratory testing, and digitally integrated clinical workflows. Diagnostic solutions that deliver rapid interpretation and facilitate ongoing monitoring can strengthen adoption as veterinary practices expand their capabilities for complex neurological cases.
France 🇫🇷
Specialized Neurology WorkflowsFrance is prioritizing more structured approaches to diagnosing neurological disorders in companion animals, creating demand for specialized imaging, laboratory testing, and referral-based expertise. Commercial opportunities lie in diagnostic platforms that improve differentiation of neurodegenerative conditions and provide veterinarians with practical evidence for ongoing case management.
Italy 🇮🇹
Accessible Veterinary NeurodiagnosticsItaly’s market priorities center on making specialized neurological diagnostics more accessible through veterinary clinics, referral centers, and laboratory networks. Providers can emphasize practical testing pathways, imaging support, and cost-conscious diagnostic packages that enable earlier investigation and continued monitoring of neurological disease in companion animals.
Veterinary Neurodegenerative Disease Diagnostics Market Share (%), by Indication, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportIndication Segment Analysis: Cognitive Dysfunction (Largest & Fastest-Growing Segment)
Cognitive dysfunction accounted for a 2026 share of 42.77% of the veterinary neurodegenerative disease diagnostics market and is also expected to experience the fastest growth across indications, reflecting the increasing recognition of age-related cognitive changes in companion animals and the need for timely veterinary assessment. Cognitive dysfunction can involve changes in memory, awareness, learning, sleep patterns, and behavior, creating a growing need for diagnostic approaches that help distinguish neurological disorders from other age-related or medical conditions. As companion animals live longer, veterinary professionals and pet owners are placing greater emphasis on identifying cognitive changes at earlier stages and supporting appropriate management strategies. Growing awareness of animal neurological health, improvements in veterinary diagnostic capabilities, and increasing willingness to pursue specialized care are further supporting demand for cognitive dysfunction diagnostics. The development of more accessible and comprehensive assessment approaches is also helping veterinarians evaluate neurological changes more systematically, strengthening the role of this indication in the broader veterinary neurodegenerative disease diagnostics landscape.
Animal Type Segment Analysis: Companion (Largest & Fastest-Growing Segment)
Companion animals represent the largest and fastest-growing animal type segment in the veterinary neurodegenerative disease diagnostics market, supported by increasing attention to the health and quality of life of household pets. Dogs and cats are increasingly regarded as long-term members of households, encouraging owners to seek veterinary care when behavioral, cognitive, or neurological changes become apparent. The aging companion animal population is also contributing to greater demand for diagnostic services associated with neurodegenerative and age-related conditions. Advances in veterinary medicine have expanded access to specialized neurological evaluations, while increasing awareness of preventive and senior-pet healthcare is encouraging earlier assessment of potential disorders. In addition, growing expenditure on advanced veterinary care and greater availability of diagnostic facilities are supporting adoption of specialized testing for companion animals. These trends are creating a broader need for reliable diagnostic solutions that can help veterinarians identify neurological conditions and guide individualized care strategies.
Diagnostic Tests Segment Analysis: Imaging (Largest & Fastest-Growing Segment)
Imaging represents the largest and fastest-growing diagnostic tests segment in the veterinary neurodegenerative disease diagnostics market, reflecting its important role in evaluating structural and neurological abnormalities in animals. Imaging-based approaches enable veterinarians to examine the brain and related anatomical structures, helping identify abnormalities and differentiate potential causes of neurological symptoms. The increasing complexity of veterinary neurological conditions is creating greater demand for diagnostic methods that provide detailed anatomical information and support more informed clinical assessment. Improvements in veterinary imaging capabilities, wider availability of specialized diagnostic facilities, and increasing adoption of advanced veterinary care are further strengthening the use of imaging-based diagnostics. Imaging can also complement clinical and neurological examinations by providing additional evidence for diagnostic decision-making, particularly when symptoms are difficult to distinguish from other age-related conditions. As awareness of veterinary neurodegenerative disorders grows and pet owners increasingly pursue advanced diagnostic care, imaging is expected to remain an important component of comprehensive neurological evaluation.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Indication | Cognitive Dysfunction, Cerebellar Abiotrophy, Spongiform Encephalopathies, Others | Cognitive Dysfunction | Cognitive Dysfunction |
| Animal Type | Livestock, Companion | Companion | Companion |
| Diagnostic Tests | Imaging, Biomarker Diagnostic Tests, Others | Imaging | Imaging |
| End Use | Veterinary Hospitals and Clinics, Veterinary Diagnostic Laboratories, Others | Veterinary Hospitals and Clinics | Veterinary Hospitals and Clinics |
| Product | Consumables, Reagents & Kits, Equipment & Instruments | Consumables, Reagents & Kits | Consumables, Reagents & Kits |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Analyst Perspective:
Clinical adoption in veterinary neurodegenerative diagnostics relies on overcoming non-invasive diagnostic barriers and validating reliable biomarker tools for early detection. The market is transitioning away from subjective evaluation toward objective, standardized methodologies, including non-invasive behavioral and physiological tracking alongside specialized imaging platforms with clinical interpretation support. Simultaneously, point-of-care biomarker testing devices and early-stage screening assays enable faster decision-making prior to severe symptom onset. However, commercial viability across diverse animal breeds and age groups requires rigorous analytical accuracy and broad population validation. Industry suppliers that successfully integrate intuitive, rapid diagnostic interfaces with dependable early-detection capabilities will capture significant advantage as veterinary care increasingly prioritizes preventive neurological management.
Top players in the veterinary neurodegenerative disease diagnostics market:
- IDEXX Laboratories (USA)
- Zoetis (USA)
- Virbac (France)
- Life Diagnostics (USA)
- ACUVET BIOTECH (UK)
- Merck & Co. (USA)
- MI:RNA Diagnostics (UK)
- Mercodia AB (Sweden)
- Antech Diagnostics (USA)
- Avacta Animal Health (UK)
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| IDEXX Laboratories (USA) | |||||||
| Zoetis (USA) | |||||||
| Virbac (France) | |||||||
| Life Diagnostics (USA) | |||||||
| ACUVET BIOTECH (UK) | |||||||
| Merck & Co. (USA) | |||||||
| MI:RNA Diagnostics (UK) | |||||||
| Mercodia AB (Sweden) | |||||||
| Antech Diagnostics (USA) | |||||||
| Avacta Animal Health (UK) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| WOORIEN Co., Ltd. | October 2024 | WOORIEN Co., Ltd. launched the MyVet CT Plus, an advanced imaging system engineered for diverse animal sizes. By accelerating image acquisition times by 45% to 80% over previous models, the solution significantly improves diagnostic workflow efficiency and high-resolution neuroimaging capabilities in veterinary diagnostic facilities. |
| Animed Veterinary Group | March 2024 | Animed Veterinary Group launched a mobile CT service across Animed Veterinary Hospital and Nine Mile Veterinary Group facilities within CVS Group Plc. The initiative expands local access to advanced point-of-care neurodiagnostic imaging, supporting earlier detection of complex neurological conditions without requiring full facility capital expenditure. |
| IDEXX Laboratories | January 2024 | IDEXX Laboratories introduced the IDEXX inVue Dx Cellular Analyzer, leveraging slide-free AI-driven imaging technology for rapid in-clinic cytology. The commercialization of this real-time diagnostic platform streamlines operational workflows and enhances immediate point-of-care cellular diagnostics across clinical veterinary practices. |
| IDEXX Laboratories | August 2020 | IDEXX Laboratories launched the ImageVue DR30 Digital Imaging System, expanding its core digital radiography diagnostic portfolio. The platform enhances imaging clarity and speed for veterinary practices, reinforcing the company's competitive positioning in diagnostic equipment offerings. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Veterinary Neurodegenerative Disease Diagnostics Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Disease Stage | Early-Stage Disease, Moderate-Stage Disease, Advanced-Stage Disease |
| Sample Type | Blood & Serum, Cerebrospinal Fluid, Urine, Tissue & Biopsy Samples |
| Diagnostic Setting | Primary Veterinary Clinics, Specialty & Referral Hospitals, Veterinary Diagnostic Laboratories, Veterinary Research Institutions |
Veterinary Neurodegenerative Disease Diagnostics Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Companion Animal Screening & Referral Patterns |
|
| Diagnostic Access & Affordability Assessment |
|
| Unmet Diagnostic Need Mapping |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
What is the market valuation of the veterinary neurodegenerative disease diagnostics market?
What are the growth projections for the veterinary neurodegenerative disease diagnostics industry?
How are advanced neurodiagnostic technologies changing veterinary neurological care?
Why are biomarker developments becoming strategically important for veterinary neurodegenerative diagnostics?
Why is cognitive dysfunction the leading indication in veterinary neurodegenerative disease diagnostics?
How is demand for imaging diagnostics growing in veterinary neurodegenerative disease care?
Why does North America lead the veterinary neurodegenerative disease diagnostics market?
How is Asia Pacific creating growth opportunities in veterinary neurodegenerative disease diagnostics?
Which companies dominate the veterinary neurodegenerative disease diagnostics landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook